LAVA Therapeutics (NASDAQ:LVTX) Trading Down 2.3%

LAVA Therapeutics (NASDAQ:LVTX)’s share price was down 2.3% during mid-day trading on Friday . The company traded as low as $2.96 and last traded at $3.03. Approximately 47,453 shares traded hands during trading, a decline of 96% from the average daily volume of 1,352,372 shares. The stock had previously closed at $3.10.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a research report on Thursday, March 21st.

LAVA Therapeutics Stock Down 2.3 %

The stock has a 50-day simple moving average of $2.90 and a 200-day simple moving average of $2.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.62 and a current ratio of 6.62.

LAVA Therapeutics (NASDAQ:LVTX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.40). The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $25.00 million. LAVA Therapeutics had a negative return on equity of 68.54% and a negative net margin of 620.09%. Equities analysts expect that LAVA Therapeutics will post -1.41 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC purchased a new stake in shares of LAVA Therapeutics (NASDAQ:LVTX) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 14,000 shares of the company’s stock, valued at approximately $47,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.